Clinical Commissioning Policy: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Rituximab will be available as a treatment option through routine commissioning for refractory SLE in adults and post-pubescent children within the criteria set out in this document. There is insufficient evidence to confirm safety or effectiveness in other age groups.

Source:

NHS England